Can Total Assets vs Total Revenue Analysis
| CANF Stock | USD 2.20 0.10 4.76% |
Can Fite financial indicator trend analysis is way more than just evaluating Can Fite Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Can Fite Biopharma is a good investment. Please check the relationship between Can Fite Total Assets and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Total Assets vs Total Revenue
Total Assets vs Total Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Can Fite Biopharma Total Assets account and Total Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Can Fite's Total Assets and Total Revenue is -0.31. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Can Fite Biopharma, assuming nothing else is changed. The correlation between historical values of Can Fite's Total Assets and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Can Fite Biopharma are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Total Assets i.e., Can Fite's Total Assets and Total Revenue go up and down completely randomly.
Correlation Coefficient | -0.31 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Total Assets
Total assets refers to the total amount of Can Fite assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Can Fite Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Revenue
Total revenue comprises all receipts Can Fite Biopharma generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most indicators from Can Fite's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Can Fite Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Can Fite's Sales General And Administrative To Revenue is most likely to decrease significantly in the upcoming years.
Can Fite fundamental ratios Correlations
Click cells to compare fundamentals
Can Fite Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Can Fite fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Common Stock Shares Outstanding | 286.4K | 358.4M | 553.1M | 815.7M | 4.3M | 4.0M | |
| Total Assets | 8.2M | 9.5M | 20.3M | 9.3M | 10.0M | 10.5M | |
| Other Current Liab | 610K | 288K | 852K | 727K | 944K | 891.4K | |
| Total Current Liabilities | 3.3M | 1.3M | 2.7M | 2.5M | 2.0M | 2.4M | |
| Total Stockholder Equity | 2.4M | 6.1M | 14.4M | 4.5M | 6.2M | 5.6M | |
| Other Liab | 2.4M | 2.2M | 3.1M | 2.3M | 2.6M | 2.0M | |
| Property Plant And Equipment Net | 118K | 123K | 185K | 126K | 81K | 87.2K | |
| Net Debt | (2.6M) | (8.2M) | (4.3M) | (2.9M) | (4.2M) | (4.4M) | |
| Retained Earnings | (110.3M) | (125.5M) | (140.7M) | (150.8M) | (158.5M) | (166.4M) | |
| Accounts Payable | 2.2M | 561K | 954K | 896K | 427K | 833.0K | |
| Cash | 2.7M | 8.3M | 4.4M | 3.0M | 4.3M | 4.6M | |
| Non Current Assets Total | 1.0M | 123K | 185K | 126K | 81K | 77.0K | |
| Cash And Short Term Investments | 2.8M | 8.3M | 19.1M | 8.0M | 8.9M | 8.4M | |
| Net Receivables | 651K | 18K | 48K | 47K | 78K | 74.1K | |
| Common Stock Total Equity | 2.4M | 2.6M | 8.2M | 33.0M | 38.0M | 39.9M | |
| Liabilities And Stockholders Equity | 8.2M | 9.5M | 20.3M | 9.3M | 10.0M | 10.5M | |
| Non Current Liabilities Total | 2.5M | 2.2M | 3.1M | 2.3M | 1.7M | 2.4M | |
| Other Current Assets | 3.7M | 1.0M | 881K | 1.1M | 986K | 1.6M | |
| Other Stockholder Equity | 103.4M | 97.4M | 93.3M | 154.2M | 163.6M | 106.5M | |
| Total Liab | 5.7M | 3.4M | 5.9M | 4.8M | 3.7M | 4.8M | |
| Property Plant And Equipment Gross | 119K | 123K | 185K | 126K | 344K | 361.2K | |
| Total Current Assets | 7.1M | 9.4M | 20.1M | 9.2M | 9.9M | 10.3M | |
| Common Stock | 2.6M | 8.2M | 33.0M | 60.7M | 69.8M | 73.2M | |
| Property Plant Equipment | 118K | 123K | 185K | 126K | 144.9K | 84.8K | |
| Net Tangible Assets | 2.4M | 6.1M | 14.4M | 4.5M | 4.0M | 7.2M | |
| Non Currrent Assets Other | 912K | (123K) | (185K) | (126K) | (113.4K) | (107.7K) | |
| Current Deferred Revenue | 469K | 334K | 818K | 783K | 622K | 594.8K | |
| Net Invested Capital | 877K | 6.1M | 14.4M | 4.5M | 6.2M | 6.0M | |
| Net Working Capital | 3.9M | 8.1M | 17.3M | 6.7M | 7.9M | 8.4M | |
| Short Term Investments | 64K | 75K | 14.7M | 5.0M | 4.6M | 4.5M |
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Quarterly Revenue Growth (0.19) | Return On Assets (0.57) | Return On Equity (1.58) |
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.